Physician profile
Nathan C Sailor
NPI 1194017160
$16,299.64
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.02 · 2020: $87.29 · 2021: $282 · 2022: $625 · 2023: $456 · 2024: $765 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,550 · Travel and Lodging: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,228.13 |
| Food and Beverage | $2,550.00 |
| Travel and Lodging | $487.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,094.00 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $624.32 | 2020-2025 | Qulipta, Vraylar, Ubrelvy |
| Braeburn INC. | $295.19 | 2023-2025 | Brixadi |
| Glaxosmithkline, LLC. | $262.11 | 2021-2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $245.23 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $222.96 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Nevro Corp. | $171.83 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.04 | 2021-2024 | Ofev, Jardiance |
| Cardiovascular Systems INC. | $154.35 | 2022 | |
| Alkermes, INC. | $136.71 | 2019-2024 | Vivitrol |
| Bard Peripheral Vascular, INC. | $103.95 | 2022 | |
| Globus Medical, INC. | $94.13 | 2025 | Vyrsa V1 |
| Bayer Healthcare Pharmaceuticals INC. | $91.15 | 2022-2023 | |
| Inari Medical, INC. | $78.76 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $76.43 | 2022-2024 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.72 | 2020-2024 | Eliquis, Camzyos |
| Pfizer INC. | $50.89 | 2024-2025 | |
| Astellas Pharma US INC | $36.99 | 2024 | Veozah |
| Mylan Specialty L.P. | $36.81 | 2022-2023 | Yupelri |
| Lilly USA, LLC | $34.47 | 2022-2023 | Mounjaro |
| Allergan, INC. | $32.45 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $29.05 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.72 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $23.42 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.00 | 2025 | Austedo Xr |
| Corcept Therapeutics | $21.78 | 2025 | Korlym |
| Exact Sciences Corporation | $19.44 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $19.21 | 2025 | Auvelity |
| Amarin Pharma, INC. | $19.20 | 2020 | |
| Abbott Laboratories | $17.58 | 2025 | Esprit |
| Antares Pharma, INC. | $16.75 | 2023 | Xyosted, Tlando, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Sailor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.